Capsida to Begin Phase 1/2 Trial of CAP-003 in Q3
Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...
Read More...
